MALVERN, PA, FREIBURG, Germany, HAIMEN, China and NIJMEGEN, the Netherlands, February 02, 2022 / B3C newswire / -- Reaction Biology, a solution provider for discovering small molecules for 20 years, has created a comprehensive platform for integrated drug discovery comprising target research, hit identification, hit-to-lead, and lead optimization: The Reaction Oncology Platform.
The Reaction Oncology Platform is based on a network of strategic partners, including oncology and biophysics by the US and Germany-based Reaction Biology, medicinal chemistry, and ADME-tox by Netherlands-based Symeres, and advanced cardiac safety/ion channel drug discovery by US/China-based PharmaCore Labs.
“Communication and problem-solving are our strengths enabling us to tackle challenging projects with close collaboration with the client and among the various teams,” said Kelvin Lam, Reaction Biology’s Vice President of Strategic Business Development. “True to our reputation as a service-oriented company, we facilitate direct contact between the client and our team of multidisciplinary scientists.”
Haiching Ma, Reaction Biology’s CSO, states: “The value of the Reaction Oncology Platform lies in the expertise of our partner network. No company can be the best in all disciplines; therefore, we choose the best partners to create a premier platform for oncology drug discovery.”
Our joint capabilities enable clients to create new chemical entities against challenging targets to fight cancer.
About Reaction Biology
Founded in 2001, the company provides a full suite of preclinical drug discovery services to over 1800 customers worldwide. The portfolio comprises target research and compound screening capabilities, a wide range of mechanistic and biophysical study options, an extensive array of cellular oncology models, and an animal facility focusing on oncology models. It maintains lab facilities in Malvern, PA, and Freiburg, Germany, with about 130 employees.
About Symeres
Symeres is the leading mid-sized European contract research, development, and manufacturing organization covering a range of drug discovery and development platforms, with over 500 scientists at six locations in the Netherlands, Finland, Sweden, and the Czech Republic. Symeres' services span from early-stage hit finding through to the delivery of Phase II clinical drug substance API, blending best in class synthetic and medicinal chemistry, ADME-Tox services via our Admescope subsidiary, PR&D, solid-state chemistry, and GMP manufacturing. www.symeres.com and www.admescope.com
About PharmaCore Labs
PharmaCore Labs (PCL) Co., Ltd is a Chinese-foreign joint venture enterprise founded in 2013. The company is located in Haimen, Jiangsu Province, with Shanghai and San Diego branch offices. It is the first company in China to provide complete preclinical cardiac safety assessment platforms and ion channel targeted drug development. PCL offers a wide range of testing platforms from the cellular level to the whole animal level, following GLP-similar guidelines for preclinical cardiac safety evaluation and ion channel targeted drug R&D.
Contact
Reaction Biology
Dr. Kelvin Lam, VP Strategic Business Development
+1 (781) 572-1121
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Animals; Drug Discovery; Chemistry, Pharmaceutical; Contract Services; Drug Design; Drug Development; North America; Germany; China; The Netherlands
Published by B3C newswire